Treatment options for refractory pain: The role of intrathecal therapy

Neurology

Volumn 59, Issue 5 SUPPL. 2, 2002, Pages

  Wallace, Mark S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BUPIVACAINE; CALCITONIN GENE RELATED PEPTIDE; CLONIDINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; OMEGA CONOTOXIN MVIIA; OPIATE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; SUBSTANCE P;

CHRONIC PAIN; COMBINATION CHEMOTHERAPY; CONFUSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; GAIT DISORDER; HUMAN; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VERTIGO;

EID: 0037056092     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.59.5_suppl_2.s18     Document Type: Review

References (103)

1. Glutamate and related amino acids in cat spinal roots, dorsal root ganglia and peripheral nerves
2. Analgesia mediated by a direct spinal action of narcotics
3. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo
4. Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibers
5. Long-term spinal analgesic delivery: A review of the preclinical and clinical literature
6. Cost analysis of two implantable narcotic delivery systems
7. Spinal cord stimulation in Belgium: A nation-wide survey on the incidence, indications and therapeutic efficacy by the health insurer
8. Dorsal column stimulation: Optimization of application
9. MMPI indicators of treatment response to spinal epidural stimulation in patients with chronic pain and patients with movement disorders
10. Dorsal column stimulation: Optimization of application
11. Spinal cord stimulation in 60 cases of intractable pain
12. Prognostic value of psychological testing in patients undergoing spinal cord stimulation: A prospective study
13. Psychological selection criteria for implantable spinal cord stimulators
14. The spinal actions of opioids
15. Substantia gelatinosa neurones hyperpolarized in vitro by enkephalin
16. Kappa-opioid receptors also increase potassium conductance
17. o mediates the coupling of the mu opioid receptor to adenyl cyclase in cloned neural cells and brain
18. Ca2+ channel inhibition by kappa opioid receptors expressed in Xenopus oocytes
19. Ca2+ channel and adenylyl cyclase modulation by cloned mu opioid receptors in GH3 cells
20. Inhibition by etorphine of the discharge of dorsal horn neurons: Effects upon the neuronal response to both high- and low-threshold sensory input in the decerebrate spinal cat
21. Multiple opiate receptor sites on primary afferent fibres
22. Release of substance P from cat spinal cord
23. Opioid modulation of capsaicin-evoked release of substance P from rat spinal cord in vivo
24. Pharmacology of mechanisms of opioid analgesic activity
25. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists
26. Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoreceptor agonists
27. Constant infusion of morphine for intractable cancer pain using an implanted pump
28. Clinical realities and economic considerations: Efficacy of intrathecal pain therapy
29. Pain treatment on outpatient basis utilizing extradural opiates. A Danish multicentre study comprising 105 patients
30. Long term intrathecal administration of morphine: A comparison of bolus injection via reservoir with continuous infusion by implanted pump
31. Comparison of intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain
32. Clinical experience of long-term treatment with epidural and intrathecal opioids - A nationwide survey
33. Long-term spinal administration of morphine in cancer and non-cancer pain: A retrospective study
34. Initial clinical experience with the SKY epidural catheter
35. Relief of continuous chronic pain by intraspinal narcotics infusion via an implanted reservoir
36. Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control
37. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders
38. Intraspinal narcotic analgesia in the treatment of chronic pain
39. Treatment of lower extremity reflex sympathetic dystrophy with continuous intrathecal morphine infusion
40. Long-term pain relief produced by intrathecal morphine infusion in 53 patients
41. Response of intractable pain to continuous intrathecal morphine: A retrospective study
42. Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine
43. Intraspinal delivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin
44. Intrathecal morphine in the treatment of chronic intractable pain
45. Long term treatment of intractable reflex sympathetic dystrophy with intrathecal morphine
46. Intrathecal infusion systems for treatment of chronic low back pain and leg pain of noncancer origin
47. Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes
48. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology
49. Management of patients receiving combined epidural morphine and bupivacaine for the treatment of cancer pain
50. Epidural versus intrathecal morphine-bupivacaine: Assessment of consecutive treatments in advanced cancer pain
51. Intrathecal infusional therapies for intractable pain: Patient management guidelines
52. Long-term intrathecal morphine and bupivacaine in "refractory" cancer pain. I. Results from the first series of 52 patients
53. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain
54. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: A retrospective analysis of 51 cases
55. Subarachnoid bupivacaine analgesia for seven months for a patient with a spinal cord tumor
56. Epidural clonidine treatment for refractory reflex sympathetic dystrophy
57. Continuous intrathecal hydromorphone and clonidine for intractable cancer pain
58. Long-term intrathecal administration of midazolam and clonidine
59. Epidural clonidine analgesia for intractable cancer pain: Phase I
60. Epidural clonidine analgesia for intractable cancer pain
61. Intrathecal morphine and clonidine in the management of spinal cord injury pain: A case report
62. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: A case study
63. Respiratory depression after intrathecal sufentanil during labor
64. Effects of perineural opioids on nerve conduction of N. suralis in man
65. Paranoid psychosis after intrathecal morphine
66. Hyperalgesic response in a patient receiving high concentrations of spinal morphine
67. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine
68. Myoclonic seizure activity with chronic high-dose spinal opioid administration
69. Meniere-like syndrome following epidural morphine analgesia
70. Epidural opioids as a cause of vertical nystagmus
71. Naloxone reversal of nystagmus associated with intrathecal morphine administration
72. The effect of unilateral dorsal root ganglionectomies or ventral rhizotomies on alpha 2-adrenoreceptor binding to, and the substance P, enkephalin, and neurotensin content of, the cat lumbar spinal cord
73. Autoradiographic localisation of alpha 2 adrenoreceptor binding sites in the spinal cord of the sheep
74. Spinal cord alpha 2-adrenoreceptors may be located postsynaptically with respect to primary sensory neurons: Destruction of primary C-afferents with neonatal capsaicin does not affect the number of [3H] clonidine binding sites in mice
75. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists
76. Release of calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal polypeptide (VIP) from rat spinal cord: Modulation by alpha 2 agonists
77. Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices
78. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels
79. 2-adrenergic agonists
80. 2 agonist, is mediated in the locus coeruleus in rats
81. Classes of calcium channels in vertebrate cells
82. Calcium channels in vertebrate cells
83. Do calcium channel classifications account for neuronal calcium channel diversity?
84. The central role of voltage-activated and receptor operated calcium channels in neuronal cells
85. Calcium channel diversity and neurotransmitter release: The omega-conotoxins and the omega-agatoxins
86. Exocytotic Ca2+ channels in mammalian central neurons
87. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications
88. Calcium and sodium channel antagonists for the treatment of pain
89. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and ailodynia
90. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega conopeptide MVIIC)
91. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals
92. Interaction of convergent pathways that inhibit N-type calcium currents in sensory neurons
93. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro
94. Peptide neurotoxins from fish-hunting cone snails
95. Characterization of two kinds of high-voltage-activated Ca-channel currents in chick sensory neurons. Differential sensitivity to dihyropyridines and omega-conotoxin GVIA
96. Chronic opioid-resistant neuropathic pain: Marked analgesic efficacy of intrathecal ziconotide
97. Analgesic efficacy of epidural ziconotide in acute postoperative pain
98. B receptor pharmacology
99. B receptors
100. Lack of effect of baclofen on substance P and somatostatin release from the spinal cord in vitro
101. A new approach to the control of central deafferentation pain-spinal intrathecal baclofen
102. Studies in the primate on the analgesic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen
103. Interaction of spinal modulatory receptor systems